Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent

摘要

The invention describes methods of treating cancer in which a therapeutically-effective amount of a 17-hydroxylase/C17,20-lyase inhibitor is administered to a subject in need thereof, including a subject with a refractory cancer and/or a subject currently undergoing another cancer treatment, wherein the 17-hydroxylase/C17,20-lyase inhibitor is administered in combination with a therapeutically-effective amount of at least one additional therapeutic agent, including, but not limited to, another anti-cancer agent or a steroid.